Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer. (3rd August 2021)

• Record Type: Journal Article
• Authors: Mauricio, Dennis; Harold, Justin; Tymon-Rosario, Joan R.; Zeybek, Burak; Santin, Alessandro D.
• Is Part Of: Expert opinion on biological therapy. Volume 21:Number 8(2021)
• Page Start: 1087
• Page End: 1096
• Publication Date: 2021-08-03
• Subjects: Anetumab ravtansine -- ovarian cancer -- cervical cancer -- clinical trials -- maytansinoid -- mesothelin -- mesothelioma -- pancreatic cancer -- anti-mesothelin -- antibody-drug conjugates; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2021.1869210
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Ovarian cancer is the deadliest gynecologic malignancy in the United States, and effective therapies for recurrent, advanced, and progressive disease are limited. Mesothelin is known to be expressed in ovarian cancers, and antibody-drug conjugates targeting mesothelin are a promising novel therapeutic agent. Areas Covered: This article reviews the currently available literature of anti-mesothelin antibody-drug conjugates as a novel treatment for ovarian cancer. Preclinical in vitro and in vivo data as well as clinical results are reviewed for each available agent. Additionally, adverse effects are covered. Expert Opinion: Anti-mesothelin antibody-drug conjugates and their combination with chemotherapeutic agents have undergone phase II trials with encouraging results and demonstrated favorable adverse effect profiles. Phase III data will be necessary to establish its role in ovarian cancer, particularly in recurrent, advanced, or progressive disease.